Mostrar el registro sencillo del ítem
dc.contributor.author
Rascol, Olivier
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Negre Pages, Laurence
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Damier, Philippe
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Delval, Arnaud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Derkinderen, Pascal
dc.contributor.author
Destée, Alain
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Fabbri, Margherita
dc.contributor.author
Meissner, Wassilios G.
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Rachdi, Amine
dc.contributor.author
Tison, Francois
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Perez Lloret, Santiago
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2021-06-16T12:14:58Z
dc.date.issued
2020-03
dc.identifier.citation
Rascol, Olivier; Negre Pages, Laurence; Damier, Philippe; Delval, Arnaud; Derkinderen, Pascal; et al.; Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study; Adis Int Ltd; Drugs And Aging; 37; 3; 3-2020; 215-223
dc.identifier.issn
1170-229X
dc.identifier.uri
http://hdl.handle.net/11336/133975
dc.description.abstract
Introduction: Immediate-release (IR) amantadine has been marketed for Parkinson’s disease (PD) therapy for 50 years, while two novel extended-release formulations have only recently reached the market in the US. Objectives: The aim of this study was to describe amantadine IR utilization patterns in the French COPARK cohort, at baseline and after 2 years of follow-up. Methods: Overall, 683 PD patients from the COPARK survey were evaluated. All patients were assessed in a standardized manner (demographics, treatments, Unified Parkinson’s Disease Rating Scale [UPDRS], Hospital Anxiety and Depression Scale, Pittsburg Questionnaire and health-related quality-of-life scales (Short Form-36 [SF-36], 39-item Parkinson’s Disease Questionnaire [PDQ-39]). Longitudinal data were only available for 401/683 patients (59%) with a median (P25–75) follow-up period of 23 months (18–31). Patients were assessed in the same way as in the baseline visit. Results: At baseline, amantadine was prescribed to 61/683 (9%) patients (median dose 200 mg/day, range 100–300 mg/day). Amantadine was initiated after a median of 7 years from PD diagnosis, and its prescription was correlated with the presence of dyskinesia (logistic regression odds ratio [OR] 3.72, 95% confidence interval [CI] 1.95–7.08) and hallucinations (UPDRS I.2) [OR 1.57, 95% CI 1.08–2.29]. After 2 years, the amantadine prescription increased from 33 (8%) patients at baseline to 54 (14%) patients in the subset of 401 patients analysed twice (p = 0.001). Among the 33 patients receiving amantadine at baseline, 9 (27%) stopped amantadine, 5 (15%) increased the dose, 6 (18%) reduced the dose and 13 (40%) stayed at the same doses. Treatment was initiated in 30/54 new patients (55%). Patients who started amantadine or increased its dose (n = 35) had more levodopa-induced dyskinesias at baseline (OR 7.02, 95% CI 3.09–15.90) and higher Mini-Mental State Examination score at follow-up (OR 1.37, 95% CI 1.06–1.79). Undergoing deep brain stimulation was related to stopping or downtitrating amantadine (OR 22.02, 95% CI 4.24–114.44; n = 15). Conclusions: In this cohort, amantadine was used in 10% of patients. Its use increased during follow-up, despite the fact that one-third of patients who received amantadine at baseline stopped taking it. Amantadine prescription was mainly correlated with the presence of dyskinesia.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Adis Int Ltd
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Parkinson's Disease
dc.subject
Amantadine
dc.subject
levodopa-related dyskinesias
dc.subject
motor fluctuations
dc.subject.classification
Neurología Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2021-03-26T19:56:05Z
dc.journal.volume
37
dc.journal.number
3
dc.journal.pagination
215-223
dc.journal.pais
Alemania
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Berlín
dc.description.fil
Fil: Rascol, Olivier. Université Paul Sabatier; Francia
dc.description.fil
Fil: Negre Pages, Laurence. Université Paul Sabatier; Francia
dc.description.fil
Fil: Damier, Philippe. Universite Lille; Francia
dc.description.fil
Fil: Delval, Arnaud. Universite de Nantes; Francia
dc.description.fil
Fil: Derkinderen, Pascal. Universite Lille; Francia
dc.description.fil
Fil: Destée, Alain. Universite de Nantes; Francia
dc.description.fil
Fil: Fabbri, Margherita. Université Paul Sabatier; Francia
dc.description.fil
Fil: Meissner, Wassilios G.. Universite Victor Segalen Bordeaux Ii; Francia
dc.description.fil
Fil: Rachdi, Amine. Université Paul Sabatier; Francia
dc.description.fil
Fil: Tison, Francois. Universite Victor Segalen Bordeaux Ii; Francia
dc.description.fil
Fil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina
dc.journal.title
Drugs And Aging
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://link.springer.com/10.1007/s40266-019-00740-2
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s40266-019-00740-2
Archivos asociados